Insider Buying: Embecta (NASDAQ:EMBC) CFO Acquires $93,400.00 in Stock

Key Points

• Embecta CFO Jacob Elguicze bought 20,000 shares at an average price of $4.67, investing $93,400 and increasing his direct ownership by 6.92% to 309,139 shares.
• Embecta’s shares rose 8.5% to $5.16, while its latest quarterly results beat expectations with EPS of $0.56 versus the $0.27 consensus and revenue of $271.7 million; however, revenue declined 8.1% year over year.
• The company faces a securities-fraud lawsuit alleging misrepresentations about its insulin pen-needle business, with an August 17 lead-plaintiff deadline. Analysts remain cautious, giving Embecta an average “Reduce” rating, while FY 2026 EPS guidance stands at $1.80–$1.90.

Embecta Corp. (NASDAQ:EMBC - Get Free Report) CFO Jacob Elguicze bought 20,000 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average price of $4.67 per share, for a total transaction of $93,400.00. Following the purchase, the chief financial officer directly owned 309,139 shares in the company, valued at approximately $1,443,679.13. The trade was a 6.92% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Embecta Stock Up 8.5%

Embecta stock traded up $0.41 during mid-day trading on Thursday, reaching $5.16. 659,113 shares of the company's stock were exchanged, compared to its average volume of 1,586,592. The business's fifty day simple moving average is $3.43 and its 200 day simple moving average is $6.46. Embecta Corp. has a one year low of $2.77 and a one year high of $15.55. The firm has a market capitalization of $292.08 million, a PE ratio of 3.48 and a beta of 0.81.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.29. The firm had revenue of $271.70 million during the quarter, compared to the consensus estimate of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The business's revenue for the quarter was down 8.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, sell-side analysts forecast that Embecta Corp. will post 1.85 earnings per share for the current year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be given a $0.01 dividend. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 annualized dividend and a yield of 0.8%. Embecta's payout ratio is currently 2.70%.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Negative Sentiment: The lawsuit, filed in federal court in New Jersey, alleges that Embecta and certain executives misrepresented the commercial stability of the company’s insulin pen-needle business. The allegations concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and have not been proven in court. EMBC Securities Lawsuit: Embecta Securities Fraud Class Action is Pending
• Negative Sentiment: A wave of investor-alert releases from SBS Law, Kaplan Fox, DJS Law, Rosen Law Firm, Hagens Berman, Faruqi & Faruqi and other firms highlights an August 17, 2026 deadline for investors to seek lead-plaintiff status. The repeated announcements increase the visibility of the legal issue and could raise concerns about potential financial, management and reputational costs for Embecta. Kaplan Fox Alerts Investors of a Securities Class Action Against Embecta
• Neutral Sentiment: The announcements primarily seek potential plaintiffs and do not represent a new court ruling, settlement or regulatory finding. Embecta’s previously reported quarterly results showed adjusted earnings and revenue above consensus, but revenue declined 8.1% year over year; the company’s FY 2026 earnings guidance remains $1.80–$1.90 per share.

Analyst Upgrades and Downgrades

EMBC has been the topic of a number of research reports. Zacks Research raised shares of Embecta from a "strong sell" rating to a "hold" rating in a report on Friday, July 17th. Wall Street Zen lowered Embecta from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Embecta from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, August 3rd. BTIG Research cut Embecta from a "buy" rating to a "neutral" rating in a research note on Tuesday, May 5th. Finally, Bank of America cut their target price on shares of Embecta from $11.00 to $3.00 and set an "underperform" rating for the company in a research report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Reduce" and an average price target of $11.00.

Hedge Funds Weigh In On Embecta

Several hedge funds have recently bought and sold shares of the company. Brooklyn Investment Group lifted its holdings in Embecta by 5.9% in the fourth quarter. Brooklyn Investment Group now owns 19,736 shares of the company's stock worth $234,000 after buying an additional 1,098 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Embecta by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company's stock valued at $209,000 after purchasing an additional 1,110 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company's stock worth $629,000 after purchasing an additional 1,159 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Embecta by 1.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company's stock valued at $1,785,000 after buying an additional 1,520 shares during the period. Finally, A&I Financial Services LLC boosted its holdings in shares of Embecta by 2.5% during the 4th quarter. A&I Financial Services LLC now owns 63,542 shares of the company's stock valued at $755,000 after buying an additional 1,556 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company's stock.

Embecta Company Profile

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source